IMR Press / EJGO / Volume 40 / Issue 1 / DOI: 10.12892/ejgo4354.2019
Open Access Original Research
The differential gene expression of Notch receptors in primary and metastatic epithelial ovarian cancer sites
Show Less
1 1st Obstetrics & Gynecology Department, Medical School, “Aristotle” University of Thessaloniki, Thessaloniki, Greece
2 Medical Oncology Department, “Euromedica” General Clinic, Thessaloniki, Greece
3 Institute of Applied Biosciences, Center of Research and Technology, Thessaloniki, Greece
4 Cytology Department, ‘‘Theagenio’’ Cancer Hospital, Thessaloniki, Greece
5 Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, United Kingdom
Eur. J. Gynaecol. Oncol. 2019, 40(1), 84–90;
Published: 10 February 2019

Purpose of Investigation: Notch signaling belongs among the candidate pathways for targeted therapies in ovarian cancer. While Notch 3 and Notch 1 overexpression has already been confirmed in ovarian carcinomas compared to their benign counterparts, the expression in metastatic sites is still not well known. The aim of the current study was to compare the relative expression of the four Notch gene receptors between primary and metastatic sites of ovarian carcinomas. Materials and Methods: Seventeen paired couples of tissues, from primary and metastatic sites of epithelial ovarian cancer, were collected during the cytoreductive surgery. For the study of the gene expression Real-Time Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) was used. The analysis of the results was performed with the Comparative CT Method (ΔΔCt Method). Results: Notch 3 and 2 were overexpressed compared to Notch 1 and 4 in both primary and metastatic sites. Notch 3 showed the highest differential expression, yet none of the four Notch genes reached statistical significance due to the differences between different samples. Conclusions: The lack of statistical difference in the expression of all four genes between primary and metastatic sites of epithelial ovarian cancer, potentially predicts same treatment response in all intrabdominal tumours and render Notch pathway a suitable and promising candidate for targeted therapies. The high heterogeneity in the expression between the samples, highlights even more the need of personalized therapies. Further studies should include more patients, examine the absolute expression, extend to all histological types, and focus on the Notch intracellular domain expression.

Ovarian cancer
Figure 1.
Back to top